NEW YORK (GenomeWeb) – Provista Diagnostics today announced it has expanded a licensing deal for certain biomarkers and autoantibody technologies identified by researchers at the Biodesign Institute of Arizona State University.
The license provides Provista access to patents, proprietary technology, materials, processing techniques, and protocols for detecting certain autoantibodies and allows the company to use certain biomarkers. The original deal forged in October 2013 gave Provista an opportunity to evaluate the applicability of the technologies to develop diagnostic products for detecting breast and ovarian cancer and human papillomavirus. Today's announcement expands Provista's evaluation license and provides it full use of the technologies for further R&D work.
The technologies were identified by Joshua LaBaer and Karen Anderson at Biodesign Institute, and "are important to Provista's diagnostics strategy," Provista President and CEO David Reese said in a statement, adding that "the combination of these biomarkers with our proprietary assays is important in the development of proteomic tests for early cancer detection."
Financial and other terms of the deal were not disclosed.